Propanc Biopharma Reports $18.9M Net Loss, Prepares for Phase Ib Clinical Trial

Propanc Biopharma, Inc. has reported significant financial developments in its latest 10-K filing for the fiscal year ending June 30, 2026. The company, which is focused on developing a novel cancer treatment using pancreatic proenzymes, reported no revenue for the fiscal year, consistent with the previous year. The net loss for the year was $18.9 million, a decrease from a net loss of $58.9 million in the prior fiscal year, indicating a substantial reduction in losses. This improvement is attributed to a decrease in stock-based compensation and professional consulting expenses, which fell from $33.6 million to $14.6 million.

In terms of operational changes, Propanc has made strides in its research and development efforts, particularly with its lead product candidate, PRP. The company has initiated preparations for a Phase Ib clinical trial, which is expected to begin in the first half of 2027, pending the successful raising of additional capital. The trial will evaluate the safety and efficacy of PRP in patients with advanced solid tumors. Additionally, the company has entered into collaborative agreements with universities in Spain to further its research initiatives, including a two-year program aimed at developing a backup clinical compound to PRP.

The company’s financial position has also seen notable changes. As of June 30, 2026, total assets were reported at approximately $12.8 million, a decrease from $19.6 million the previous year. This decline is primarily due to a reduction in cash reserves, which fell from $12.1 million to $832,006. Current liabilities also decreased significantly from $5.6 million to $3.4 million, reflecting a reduction in convertible debt and other obligations. However, the company continues to face challenges related to its liquidity, as it reported negative working capital and a reliance on debt and equity financing to sustain operations.

Propanc's employee headcount remains low, with only two full-time employees as of the end of the fiscal year. The company has indicated plans to expand its team as it progresses through clinical development stages. The filing also highlighted the company's ongoing efforts to address material weaknesses in its internal controls, which have been identified as a risk factor for future operations. Management is actively seeking to enhance its accounting and financial personnel to improve oversight and compliance.

Looking ahead, Propanc Biopharma is focused on securing additional funding to support its clinical trials and operational needs. The company has expressed optimism about the potential market for its cancer treatment, particularly given the high mortality rates associated with pancreatic and ovarian cancers. The global metastatic cancer treatment market is projected to reach $111 billion by 2027, presenting a significant opportunity for Propanc if its clinical trials yield positive results. However, the company acknowledges the inherent risks and uncertainties associated with drug development and the need for continued financial support to achieve its strategic objectives.